<DOC>
	<DOCNO>NCT01709409</DOCNO>
	<brief_summary>The purpose study see medication call Curosurf reduce length time small premature baby Respiratory Distress Syndrome ( immature lung ) RDS , stay ventilator , compare standard medication call BLES . Curosurf medication already used country around world yet Canada . Babies bear 32 week gestation frequently need respiratory support birth , include place breathing machine respirator . The common reason Respiratory Distress Syndrome ( RDS ) whereby immature lungs n't produce enough surfactant , soapy like substance help air sac open close . Our current standard treatment surfactant call BLES . Curosurf contain active ingredient per volume therefore amount small . The investigator hypothesize baby receive Curosurf able remove ventilator sooner . Babies study 50/50 chance receive either Curosurf BLES investigator monitor progress Neonatal Intensive Care Unit admission . The study take place Canada . The goal enroll 88 baby . There extra test ( blood test X-Rays ) return visit hospital purpose study .</brief_summary>
	<brief_title>A Multi-center Trial Determine CurosurfÂ® Reduces Duration Mechanical Ventilation Very Preterm Infants</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Poractant alfa</mesh_term>
	<criteria>1 . Infants bear 24+0 31+6 week gestational age , admit study center 2 . Infants RDS require intubation surfactant therapy within 48 hour birth 1 . Any infant 48 hour age 2 . Any infant pulmonary hemorrhage 3 . Any infant lifethreatening congenital anomaly one consider nonviable 4 . Any infant rescue high frequency ventilation 5 . Any infant know require early intubation ventilation surgical treatment congenital anomaly 6 . Any infant anomaly upper low airway mandible precluding use nCPAP 7 . Any infant born prolong premature rupture membrane ( &lt; 22 week GA &gt; 28 day prior delivery ) 8 . A parent/LAR incapable , unwilling , give consent 9 . Participation another clinical trial placebo , drug , biological , device conduct provision protocol 10 . Any reason deem significant Investigator</criteria>
	<gender>All</gender>
	<minimum_age>24 Weeks</minimum_age>
	<maximum_age>31 Weeks</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prematurity</keyword>
</DOC>